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Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterised by 
impaired communication and social interactions, and repetitive behavioural patterns. 
These patterns are thought to be dysfunction symptoms in executive processing, which 
impact other cognitive functions as attention or cognitive flexibility. In the last years, 
several studies have shown that certain intestinal bacteria may play a role in shaping 
cognitive networks encompassing emotional and social domains. Furthermore, the 
existence of a microbiota-gut-brain axis is known, establishing several mechanisms by 
which microbiota may modulate brain development, function and behaviour including 
immune, endocrine and neural pathways. Since aetiology of ASD is largely unknown, 
some studies have shown that intestinal bacteria may be involved in its pathogenesis. The 
aim of this review is to focus on the role of gut-brain axis in ASD and, specifically, on 
the role of gut-brain axis on the executive functions. Firstly, we summarise the relation 
between the gastrointestinal and cognitive symptoms of ASD patients. In addition, we 
highlight the evidence that support and emphasise gut microbiota implication, and the 
putative mechanism underlying the gut-microbiota in this population. Finally, we present 
evidence from preclinical and clinical studies regarding microbiota modulation and their 
effects on cognitive symptoms, specifically in that related to the executive function. In 
conclusion, microbiota manipulation could be a positive intervention in the improvement 
of ASD symptoms. However, more research evaluating the role of microbiota in ASD 
cognitive symptoms is needed.   
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1. AUTISM SPECTRUM DISORDERS (ASD): GASTROINTESTINAL AND 
COGNITIVE SYMPTOMS. 
Autism spectrum disorder (ASD) is a neurodevelopmental condition that is characterised 
by stereotyped behaviour and a deficiency in the individual’s ability to socialise, 
communicate, and use imagination (Lázaro et al., 2016). Estimates of the prevalence of 
the disorder have been moving towards an apparent increase in rates. Nowadays it is 
estimated that 1 in 68 children have ASD (World Health Organization (WHO), 2017). 
Nevertheless, it is still not known as to why autism incidence increased rapidly during the 
1990s and is still increasing in the 2000s. There are many possible explanations for this 
apparent increase in prevalence, including greater awareness, the expansion of diagnostic 
criteria, better diagnostic tools and better communication (WHO, 2017). 
Despite its increasing prevalence, ASD aetiology is still unknown. However, this disorder 
is associated with neural development, and recent evidence supports the hypothesis of a 
complex and highly heterogeneous genetic aetiology, and points to a combined effect 
between the environment and various different genes (Lázaro, 2016). In addition, there is 
an intriguing commonality among patients that is not well understood: the predominance 
of ASD in males, given that ASD presents a 4:1 male bias, pointing to a female protective 
factor, although more research is required in this sense (Werling, 2016; Kopec et al., 
2018). 
This disorder shows a significant comorbidity with other conditions. The most commonly 
associated impairments are epilepsy, sleep disturbances or anxiety and depression. 
Intellectual disability, sensory dysfunctions and attention deficits, as well as 
gastrointestinal (GI) problems and immune deficiency, have been reported in recent 
studies and have acquired great relevance in order to find an explanation for autism (Lyall 
et al., 2017). 
Other common symptoms in ASD are cognitive symptoms: some attention difficulties in 
children with ASD have been noticed, mainly having trouble shifting attention. In 
addition, some children with ASD have difficulties with selective attention, indicating 
which environmental information should be focused on, particularly when exposed to a 
stimulating sensory environment (Hazen et al., 2014). Alongside these difficulties, 
executive function deficits in children with ASD have been widely documented. There is 
converging evidence to suggest that children with ASD have poor planning and 
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flexibility. However, behavioural regulation executive skills have been ambiguous, such 
as inhibitory deficits and  research on working memory (Freeman et al., 2017). Beyond 
these problems, Martos-Pérez and Paula-Pérez (2011) noticed that ASD individuals are 
not available to ascribe a mental or emotional state to other people, or find a meaning for 
their actions. However, more research is needed in order to understand the role of these 
functions in ASD.  
Children with ASD are regularly affected by GI problems. Even a higher risk of problem 
behaviours has been reported in individuals with ASD and GI symptoms (Grossi et al., 
2016). The most comorbid GI symptoms in ASD are constipation, bloating, and 
diarrhoea. Other studies (Celia et al., 2016) have observed the presence of reflux, colitis/ 
inflammatory diseases, food intolerances, or symptoms of irritable bowel syndrome as 
well as loose stools, undigested food, or abdominal distension. A recent review of GI 
symptoms in ASD (Holingue et al., 2018) has determined a prevalence range for 
constipation of 4.3–45.5%, for diarrhoea of 2.3–75.6%, and for any or more than one 
symptom of 4.2–96.8%. The range prevalence of GI symptoms shows a possible link 
between the gut microbiota and the ASD.  
Beyond this, several studies (Adams et al., 2011; Louis, 2012) have reported that autistic 
individuals exhibit a change in the stability, diversity, composition, and/or metabolism of 
gut bacteria. Both gut bacteria and microbial metabolites changes reported in ASD 
patients will be detailed in the second section of this review. 
After birth, the gut is rapidly colonised by bacteria achieving concentrations up to 1012 in 
the colon (Ohland & Jobin, 2015). This composition depends on different factors: type of 
delivery (vaginal or caesarean section), diet (breast milk or formula), or consumption of 
antibiotics, among others. The microbiota is considered stable and similar to adult 
microbiota around the child’s 2nd year of life. An adult’s microbiota is composed of 30 
species of Bifidobacterium, 52 species of Lactobacillus, and others, such as Streptococcus 
and Enterococcus – ( Wallace et al., 2011; Salazar et al., 2014). 
In the last years, the gut microbiota has been the focus for many researchers and studies, 
given that a healthy gut flora is largely responsible for overall health of the host. Normal 
gut microbiota has several and specific functions in the host’s nutrient metabolism, 
xenobiotic and drug metabolism, maintenance of structural integrity of the gut mucosal 
barrier, immunomodulation, and protection against pathogens (Jandhyala et al., 2015). 
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Even, the gut microbiota has demonstrated the capacity of modulate emotion, motivation 
and higher cognitive functions (Carabotti et al., 2015), this modulation occurs through 
the Gut-Brain Axis (GBA). The GBA is a bidirectional communication network between 
the gut and brain, in which the communication occurs via three different pathways: 
neural, endocrine and immunological (Mayer et al., 2015).  
Although the aetiology of ASD is unclear and there are different hypotheses regarding it, 
ASD has been related to some epigenetic conditions. Both pre-natal (such as maternal 
obesity or maternal inflammation) and post-natal factors (such as delivery, stress, diet or 
antibiotic treatment) are associated to a modification of gut microbiota composition, 
perturbing microbiota-gut-brain axis (Osokine & Erlebacher, 2017; Cristiano et al., 
2018). In this review, we are focusing on the role of the GBA in ASD and, specifically, 
on the role of the GBA in the executive functions.  
2. THE ROLE OF MICROBIOTA-GUT-BRAIN AXIS IN ASD 
As previously detailed, there is extensive evidence that supports changes or alterations in 
the gut composition in ASD patients compared to the control group. Therefore, in this 
section we detail, as far as we know, the research that supports and emphasises the gut 
microbiota implication, as well as our intention to explain the putative mechanism 
underlying the gut-microbiota in this clinical population. There are several pathways that 
support the relation between the gut and ASD: para-cresol (p-cresol), amines produced 
by degrading-protein bacteria (Macfabe, 2012), an interrelation between Clostridium 
bacteria colonisation of the intestinal tract and autism (Argou-Cardozo & Zeidán-Chuliá, 
2018), overproduction of short-chain fatty acid (SCFA) (Macfabe, 2012; Wang et al., 
2012), microbiota-related alterations in bile acid and tryptophan metabolism (Golubeva 
et al., 2017), through serotonin as the nexus for the gut-brain axis in ASD (Israelyan & 
Margolis, 2018), among others. 
Bacterial changes in ASD 
Firstly, children with ASD appear to have more bacterial diversity and possess lower 
overall abundance of potentially beneficial taxa, such as Bifidobacteria and Akkermansia 
(Sanctuary et al., 2018), among other imbalances. For example, there is an observation of 
a significant increase in the Firmicutes/Bacteroidetes ratio in autistic subjects relative to 
normal subjects, or two times more abundant Candida in autistic individuals than in 
normal individuals (Q. Li et al., 2017). 
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The specific species of microbes altered in ASD versus controls vary from studies (Table 
1). Different studies in humans have highlighted an increase of Phylum Bacteroidetes and 
Proteobacteria, and a decrease of Phylum Firmicutes and Actinobacteria in ASD children 
in comparison to non-autistic children. These studies have also observed a reduction in 
Prevotella, Coprococcus, Enterococcus, Lactobacillus, Streptococcus, Lactococcus, 
Staphylococcus, and Bifidobacterium, and an increase in Rominnococcus, Sutterella, 
Desulfovibrio, Prevotella, Pseudomonas, Aeromonas, Enterobacterias and Clostridium 
in ASD children. Several studies agree that the genus Clostridium increases in autistic 
children, causing higher propionic acid (PPA) levels and interactions with beneficial 
bacteria (such as Bifidobacterium) (Larroya-García et al., 2018). 
INSERT TABLE 1 AROUND HERE 
All these changes are occasionally reported as dysbiosis or dysbiosis intestinal. However, 
the use of term dysbiosis could be inadequate in ASD as it is not clearly established as a 
cause or an effect, although perceived as a real phenomenon. In this way, according to 
Hooks and O’Malley (2017) the term dysbiosis must be considered when establishing 
microbiota causality in disease, and, at this moment, it is unclear if these modifications 
cause particular ASD symptoms or they are a consequence. Mayer et al. (2014) point out 
that it is likely that GI symptoms in ASD patients are caused by multiple factors: central 
sensory augmentation, altered modulation of GI function (motility, secretion, and 
epithelial permeability) by the autonomic nervous system, altered regulation of motility 
and secretion by the enteric nervous system, or a combination of these factors. Thus, 
research with larger samples taken at different time points to asseverate dysbiosis in ASD 
is required. 
Microbial metabolites changes in ASD 
Moreover, bacteria can ferment dietary proteins through the putrefaction process. As a 
result of this process, gut health can be determined by products of microbial putrefaction. 
There are different microbial metabolites that have been associated with reduced viability 
of colonic epithelial cells in vitro, increased intestinal permeability, DNA damage and the 
inhibition of cellular respiration in colonocytes (Sanctuary, 2018).  
A relationship between the degree of myelination and the intestinal bacterial composition 
has been postulated, thus, a functional microbiota provides adequate myelination in the 
prefrontal cortex (Hoban et al., 2016). In this way, changes in the gut microbiome were 
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shown to alter the composition of the microbial metabolome affecting highly permeable 
bioactive compounds, such as p-cresol, which could impair oligodendrocyte 
differentiation in vitro (Ntranos & Casaccia, 2018). Dysregulated myelination in the 
prefrontal cortex is then able to affect behavioural responses in mice, shifting them 
towards social isolation. In addition, the reduced social interactions could then limit 
microbial exchange (reviewed in Ntranos and Casaccia (2018). 
Although there are several microbial metabolites, literature has mainly focused on p-
cresol, an aromatic molecule from the environment or synthetized by intestinal bacteria 
from tyrosine and toluene (Yokoyama & Carlson, 1981; Selmer & Andrei, 2001; Cafaro 
et al., 2005). Usually, environmental exposure to p-cresol occurs through the skin, as well 
as the gastrointestinal and respiratory systems. The distribution of cresol is practically 
throughout body, found in blood, the kidneys, lungs and brain among others (Gadaskina 
& Filov, 1971; Green, 1975). This fact might indicate effects of p-cresol in the central 
nervous system (CNS). Additionally, it has been suggested that the urinary p-
cresol contributes to the impairment of autism and gut function (Persico & Napolioni, 
2013). It has also been proposed as a biomarker of autism liability in small children 
(Altieri et al., 2011). In this sense, high levels of urinary p-cresol in young ASD children 
are known, which are influenced by increased intestinal transit time and chronic 
constipation (Gabriele et al., 2016). Both p-cresol and gut-microbiota seem to be related 
by gender. The liability of p-cresol as a biomarker is especially useful in females and 
more severely affected males (Altieri, 2011). Nonetheless, the gut microbiota seemed to 
differ in a sex-specific manner (Suzuki et al., 2017), which is possibly due to the possible 
interaction between the microbiome, immune system and sex hormones (Kopec, 2018).  
Furthermore, ASD children have higher faecal p-cresol and possibly lower GABA 
concentrations (Kang et al., 2018), and ASD have altered metabolite profiles in faeces 
when compared with neurotypical children and warrant further investigation of 
metabolites in larger cohorts. Other authors suggest an increase in GABAergic inhibitory 
neurons due an overexpression FOX/G1 gene (Mariani et al., 2015). 
On the other hand, p-cresol and 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (a 
multiple Clostridia species metabolite) inhibit a crucial enzyme that converts dopamine 
to norepinephrine, the dopamine-beta-hydroxylase. The presence of p-cresol in the CNS 
would lead an excess of dopamine and its metabolites like homovanillic acid (DeWolf et 
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al., 1988; Southan et al., 1990; Keşli et al., 2014; Xiong et al., 2016). In fact, severity in 
autism symptoms has been related to urinary homovanillic acid levels and alterations in 
the brain catecholamines production (Garnier et al., 1986; Martineau et al., 1992). 
Binding the capacity of serotonin to its receptor was also studied, leading to a decrease in 
the serotonin transporter in the medial frontal cortex and low serotonin transporter 
synthesis altering serotoninergic terminals (Makkonen et al., 2008). Moreover, mutations 
in the SLC6A4 gene, which encodes the serotonin transporter, have been identified in 
ASD individuals (Adamsen et al., 2014). Also, the concentration of other amino acids, 
such as glutamate, has been altered in ASD (Lussu et al., 2017). Moreover, the severity 
of symptoms is correlated with the decrease of glutamate levels in the basal ganglia and 
anterior cingulate cortex (Horder et al., 2013; Tebartz van Elst et al., 2014), structures 
related with executive function (Lanciego et al., 2012; Bledsoe et al., 2013). All data 
suggest that monoaminergic systems are affected in ASD patients. 
Concerning  other microbial metabolites, a recent study has shown the existence of high 
concentrations of isopropanol in faeces (Kang, 2018), however the origin of the increased 
isopropanol is unknown and requires more research, given that isopropanol has not been 
investigated previously in children with ASD. Though, this finding is remarkable, 
considering that isopropanol is a neurotoxic organic solvent that contributes to the CNS 
and respiratory depression.  
There is growing evidence that other compounds derivate from fermentation of enteric 
bacteria as SCFAs, which are present in ASD. One of them is PPA, synthetised by 
Clostridia, Bacteriodetes and Desulfovibrio. Intestinal absorption and transport of PPA 
to the blood and brain were reported many years ago (Cummings et al., 1987; Karuri et 
al., 1993). After administration of PPA, hippocampal expression of several genes was 
altered in rats. Thus, GFAP, the gene encoding intermediate filaments of astrocytes, and 
TNF-α were increased and OCT4, the undifferentiated embryonic stem cell-related gene, 
was decreased (Choi et al., 2018). Moreover, rats treated with PPA showed deficits in 
social behaviours and cognition (Shultz et al., 2009; MacFabe et al., 2011), using supra-
physiological concentration. The underlying mechanisms of influences by PPA in ASD 
were considered through the altered mitochondrial activity. For instance, acyl-carnitine 
and all proteins of complex I of the electron transport chain were augmented, suggesting 
that these increments in mitochondrial respiratory function would explain the greater 
sensitivity in oxidative stress (Frye et al., 2013; Rose et al., 2014, 2017). These negative 
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effects depend on concentrations and exposition time to PPA. An increase in reactive 
oxygen species has been shown in the mitochondrial membrane in lymphoblastic cell 
lines using a high concentration without exceeding intestinal absorption concentration of 
PPA in humans. Interestingly, it has been reported that some ASD individuals may use 
PPA as an energy source, suggesting that they develop adaptive mechanisms against 
mitochondrial alterations in the presence of high levels of PPA (Frye et al., 2016). 
Likewise, the immune system and inflammatory processes might be the cause GI 
symptoms appearing in ASD according to research. Thus, lipopolysaccharides (LPS) 
produced by intestinal microbiota are able to stimulate pro-inflammatory cytokines and 
cytokines production such as IL-6, TNF-α, IL-8 and IFN-γ among others, which were 
increased in the cortex of the brain and in the blood in individuals with ASD in 
comparison to non-ASD individuals (Croonenberghs et al., 2002; Ashwood & Wakefield, 
2006; X. Li et al., 2009).  
All the above mentioned, alongside evidence indicating changes in the composition of 
the commensal microbiome, can conclude that complex behaviours can be altered, 
including anxiety-like behaviour, emotional or depressive behaviour, and locomotor 
activity, among others, pointing to the possible relationship between the GBA and the 
development of  ASD (Hsiao et al., 2013; Hsiao, 2014).  
3. GUT-BRAIN AXIS: THE ROLE OF MICROBIOTA IN EXECUTIVE 
FUNCTION 
Currently there is a growing interest in the role of microbiota in cognitive behaviour. In 
this section, we summarise the evidence from both preclinical and clinical studies 
regarding microbiota modulation and the effects on cognitive symptoms, specifically in 
that related to the executive function.   
As previously detailed, executive dysfunction is very frequent in ASD children, as they 
often present difficulties with planning, and cognitive flexibility. In addition, this 
population also shows more deficits in shifting attention, sustained or selective attention, 
response inhibition, and working memory. Nonetheless, ASD can present an executive 
dysfunction in monitoring, a poorer performance on preparatory processing, a deficit in 
verbal fluency, and an inadequate function concerning concept formation, when the 
performance is compared to the control group (Hill, 2004; Margari et al., 2016). 
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According to Shaheen (2014), executive functions are often associated with the 
maturation of the prefrontal cortex. In fact, young children with rudimentary 
neurodevelopment of the prefrontal cortex acquire ways to inhibit impulses and regulate 
behaviour from a very early age. However, it is increasingly recognised that there are 
multiple areas of the brain involved in executive functions (e.g., dorsolateral prefrontal 
cortex, anterior cingulate cortex, orbitofrontal cortex, medial prefrontal cortex), and that 
each of these brain regions have extensive functional connections to other regions of the 
brain (subcortical areas and brain stem) (Miller et al., 2015).  
On the other hand, a relation between obesity and cognitive impairment through the GBA 
has been found, although evidence in this sense is highly limited. Dietary patterns in ASD 
based on involving excessive consumption of processed snacks and calorie-dense foods 
may also explain emerging evidence of a higher incidence of obesity (McElhanon et al., 
2014). According to Miller et al., (2015) and Solas et al. (2017), this type of diet 
influences gut microbiota, producing bacteria modifications and inflammation, and this 
could affect cognitive functions, although the precise mechanisms that underlie the 
connections between obesity and the risk of cognitive impairment are still largely 
unknown.  
Some clinical studies have related obesity with the risk of developing mild cognitive 
impairment related to executive function deficits (Solas, 2017). In fact, a recent review 
has focused on the relation between hormonal alteration in obesity (Ghrelin, Glucagon-
like Peptide 1) and their association with cognition and executive function. Thus, ghrelin 
activates hippocampal regions relevant for learning and memory or the Glucagon-like 
Peptide 1 also signals multiple brain regions, including the hypothalamus and the 
prefrontal cortex. In addition, adipose tissue has shown the capacity to produce substances 
such as leptin, IL-6, TNF-α, and such substances are associated with executive functions 
(Miller, 2015).  
In light of the above, we could infer that if the executive function is related to obesity and 
the putative mechanism involved, the gut-microbiota have a relevant aspect in the 
modulation in the executive function, given that obesity appears to be related to an altered 
gut-microbiota (Castaner et al., 2018). Since findings indicate that the presence of 
commensal bacteria in the gut is critical for normal brain development, it raises the 




Other data showing the relationship between the GBA and executive function are 
provided by Labus et al. (2017), who observed a moderate correlation for the Clostridia 
in patients diagnosed with irritable bowel syndrome with several sensory integration 
regions including the thalamus, basal ganglia (caudate nucleus, putamen, pallidum, 
nucleus accumbens), and the superior part of the precentral gyrus (motor cortex). Similar 
correlations were found for the anterior insula and ventral prefrontal regions. It is 
interesting to note that the Clostridia are an abundant strain in ASD patients (Kim et al., 
2018). 
The microbiome–gut–behaviour axis, as part of the GBA, is being increasingly 
recognised as a modulator of social behaviour, and as an important regulator of prefrontal 
cortex myelination, a key brain region for driving complex cognitive behaviour (Ntranos, 
2018).  
Therefore, manipulations of microbiota with probiotics or diet could produce changes in 
cognition and executive functions through the GBA. This hypothesis is supported, among 
others, by the data of Ong et al. (2018), who utilised diffusion tensor imaging to show 
that overall changes in white matter structural integrity occurred in a diet-dependent 
manner, changing the microbiome. In fact, results of a clinical study performed on healthy 
women who intake fermented milk products with probiotics for 4 weeks showed a 
positive correlation to task-induced periaqueductal gray activity with cortical modulatory 
regions (medial and dorsolateral prefrontal cortex) (Tillisch et al., 2013). In this sense, 
Hoban et al. (2016) assume the potential therapeutic target of probiotics for psychiatric 
disorders involving dynamic myelination in the prefrontal cortex. 
In addition, another specific target through a dietary intervention could be interventions 
that modify the microbial metabolites implicated in ASD. In that sense, dietary 
interventions could modify the p-cresol level, the metabolite mainly implicated in the 
microbiome GBA. For example, a daily consumption of 40 g of dark chocolate during a 
period of 2 weeks reduces the urinary excretion of the stress hormone cortisol, implicated 
in the GBA, and catecholamines and partially normalised stress-related differences in 
energy metabolism and gut microbial activities (such as, p-cresol sulphate) (Martin et al., 
2009). Likewise, the consumption of 57 g of pistachios on a daily basis in prediabetic 
patients for 4 months decreased the p-cresol sulphate level in comparison to the control 
group (Hernández-Alonso et al., 2017). Moreover, the consumption of wheat bran 
extract (10 g/daily) during a period of 2 weeks decreases the urinary p-cresol excretion 
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and faecal bifidobacteria levels were significantly increased after a daily intake of 10 g, 
so then the gut health could be improved (François et al., 2012). In addition, probiotics 
and symbiotics have shown a reduction in the p-cresol level, the daily administration of 
a symbiotic formulation during 4 weeks reduced the plasma p-cresol level in CKD 
patients (Guida et al., 2014). Another study performed on a similar population who 
received a symbiotic therapy over 6 weeks (4-week washout) has shown a decrease in 
serum PCS and the stool microbiome was favourably modified (Rossi et al., 2016). In 
addition, the symbiotics administration during 30 days have shown to decrease the plasma 
p-cresol level in kidney transplant patients (Guida et al., 2017). 
Other data showing the effects of dietary interventions in ASD are provided by BTBR 
mice, that is, one of the most widely used model of ASD (Needham et al., 2018). Social 
behaviour deficits in BTBR mice are associated to marked GI distress, evidenced by 
changes in intestinal permeability, transit and the enteric nervous system morphology, as 
well as altered microbiota composition (Golubeva, 2017). In that sense, dietary 
supplementation of a precursor tryptophan enhanced social interaction preference in 
BTBR (Zhang et al., 2015). Moreover, a ketogenic diet produced microbiota alterations 
such as a low Firmicutes to Bacteroidetes ratio in both caecal and faecal matter (Newell 
et al., 2016). In addition, changes to a few bacterial taxa that are also sex-specific have 
been recently reported in the BTBR intestine (Coretti et al., 2017). 
According to such evidence, we could hypothesise that dietary interventions could be 
effective in ASD and we could expect a change in the cognitive and behavioural ASD 
symptoms through the GBA alteration. However, the preclinical and clinical studies 
performed in ASD, in which the intervention involved a microbiota modulation (faecal 
transplant, probiotics, symbiotics, or prebiotics) and their effects on behaviour symptoms, 
is highly limited (Table 2).  
INSERT TABLE 2 AROUND HERE 
Preclinical studies 
The only preclinical study found to our knowledge in an animal model of ASD was that 
performed by Hsiao et al. (2013) who administrated Bacteroides infantis on a daily basis. 
Their results showed correct gut permeability and alterations in microbial composition 
and ameliorates ASD-related defects in communicative, stereotypic, anxiety-like and 
sensorimotor behaviours. These results support a gut-microbiome-brain connection in 
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ASD and identify a potential probiotic therapy for GI and behavioural symptoms in 
autism. Although there are other studies in which the effect of microbiota in the ASD is 
assessed, as far as we know, no one assesses the effect of a microbiota modulation in ASD 
symptoms.  
Clinical studies 
There has also been some interesting progress in humans in this field. The main 
intervention studied in the clinical studies that implicate a microbiota modulation is 
through the probiotic administration and there is one research that used faecal 
transplantation. In the study performed by Sichel, Roberts, Sichel, and Sichel (2013), the 
administration of a probiotic mixture during 6 months in 33 children diagnosed by ASD 
showed a decrease in diarrhoea severity and constipation severity (n=25). Overall, 88% 
reported a decrease in total ATEC score, signifying an improvement of ASD symptoms. 
Mean ATEC values decreased from 72.8 prior to treatment to 58.3 following treatment 
initiation. Participants also had significant improvements in all ATEC domains 
(speech/language/communication, sociability, sensory/cognitive awareness, and 
health/physical/behaviour). However, these results are not significant due to the study 
design not extrapolating the results.  
Another microbiota modulation studied is antibiotic administration. After 8 weeks of 
Vancomycin treatment, the authors reported a clear improvement in communication and 
behaviour (Sandler et al., 2000). After the treatment period with Vancomycin, the authors 
administered a probiotic mixture during 4 weeks. The gains observed during the antibiotic 
treatment did not endure during the probiotic phase, contrary as could be expected. These 
results were explained in the difficulty in disguising the taste and the poor adherence or 
compliance to the probiotic treatment (Sandler, 2000). Similar results were reported in a 
probiotic-placebo controlled cross-over designed study, in which after 3 weeks of 
probiotic (Lactobacillus plantarum WCFS1) administration did not show any effect on 
the psychological assessment as compared to the placebo group (Parracho et al., 2010). 
Results from recent small open-label study developed by Kang et al. (2017) suggest that 
microbiota transplantation could be a safe intervention in ASD children (7-16 years). This 
intervention shows significant improvement in GI and ASD-related symptoms, that 
improvements were maintained at least during 8 weeks. In addition, a significant negative 
correlation between changes in GSRS and PGI-II were reported by the authors, 
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suggesting that GI symptoms worsen directly with ASD behaviours, and that these can 
be altered via microbiota transplantation. Regarding ASD-related symptoms, the data 
showed an improvement in irritability, hyperactivity, lethargy, stereotypy and aberrant 
speech, as well as in adaptive behaviours (communication, daily living skills and 
socialisation). 
With regard to the type of intervention, there are no data from microbiota transplantation 
previous to 7-year-old participants. As Kang et al. (2017) detailed, the US Food and Drug 
Administration (FDA) limited their participants to children ages 7–17 years, since most 
faecal microbiota transplantation studies have been conducted on adults, and there was 
very limited data and knowledge of the impact and usage of faecal microbiota transplant 
for younger children.  
Although the studies evaluating the role of microbiota in the modulation of cognitive 
symptoms of ASD are limited, other research has pointed out this effect in other related 
clinical populations (Roman, Abalo, et al., 2018). In that sense, probiotic supplementation 
(Lactobacillus Rhamnosus GG) during the first 6 months of life may reduce the risk of 
neuropsychiatric disorder development (attention deficit hyperactivity disorder or 
Asperger syndrome) later in childhood, possible by mechanisms not limited to gut 
microbiota composition (Pärtty et al., 2015). Another study performed in very premature 
babies concluded that the administration of a probiotic combination (Bifidobacterium 
infantis, Streptococcus thermophilus and Bifidobacterium lactis) soon after birth until 
discharge home or term-corrected age did not adversely affect neurodevelopment or 
behaviour in early childhood (Jacobs et al., 2017).   
A recent study performed in myalgic encephalomyelitis or chronic fatigue syndrome 
show large effect size estimates in several cognitive outcomes after administration during 
4 weeks of an antibiotic (Erythromycin) and probiotic (Lactobacillus rhamnosus, 
Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium longum) therapy taken on 
alternate weeks. The cognitive outcome suggested an improvement in sustained attention 
from baseline to post, and also indicated improvement in processing speed, cognitive 
flexibility, story memory and verbal fluency (Wallis et al., 2018). Another recent study 
conducted on a similar clinical population, fibromyalgia patients, concluded that the daily 
administration of probiotics (Lactobacillus Rhamnosus GG, Casei, Acidophilus, and 
Bifidobacterium Bifidus) during 8 weeks improves impulsivity and decision-making in 
these patients (Roman, Estévez, et al., 2018). 
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Another population in which the probiotic has shown a positive effect is on HIV patients, 
who were treated during 6 months with a multi-strain probiotic (Lactobacillus plantarum, 
Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus paracasei, 
Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus acidophilus, Bifidobacterium 
longum, and Bifidobacterium infantis). The authors specifically reported an improvement 
of short and long memory and abstract reasoning (Ceccarelli et al., 2017). 
Concerning memory cognitive dimension, Benton et al. (2007) found an unexpected and 
possibly coincidental finding: a poorer performance on two measures of memory after the 
administration of Lactobacillus Shirota over 3 months on healthy subjects (Benton et al., 
2007).  
However, other studies have not reported a positive effect or superior to probiotics in 
comparison to the placebo on cognitive improvement, for example, the administration of 
Lactobacillus rhamnosus (JB-1) in healthy males during 8 weeks was not superior to 
placebo in visuospatial memory performance, attention switching, and rapid visual 
information (Kelly et al., 2017). However, this probiotic had shown a positive effect in 
preclinical studies, and the actual challenge is translating the promising preclinical studies 
to healthy human participants. Whereas the administration of Bifidobacterium longum on 
healthy male volunteers during 4 weeks showed a subtle improvement in visuospatial 
memory performance (Allen et al., 2016). 
The aim of this review is focused on the role of gut-brain axis in ASD and, specifically, 
the role of the gut-brain axis on executive functions. In the first section, we have provided 
a brief view in relation to the link between cognitive symptoms and GI symptoms in ASD. 
This relation makes us think about an altered gut microbiota and the possible relation 
through the gut-brain axis. Thus, in the second section, we reported bacterial and 
microbial metabolites changes reported in ASD patients and their relation with cognitive 
modulation. Finally, in the third section we detailed all the evidence, to our knowledge, 
available concerning the different microbiota modulation (antibiotic, probiotic, faecal 
transplantation, and others). 
This review has detailed extensive and different hypotheses in which the ASD gut-
microbiota is altered, however, it is not clear if the microbiota altered is a consequence of 
ASD symptoms or vice versa, so then more research is needed to disclose this important 
aspect and to allow, or not defined, ASD as a related dysbiosis intestinal pathology 
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(Mayer et al., 2014; Hooks & O’Malley, 2017). Therefore, preclinical and clinical studies 
are designed to specifically evaluate the causal relationship between these factors and to 
obtain a better understanding of the role of the GBA in ASD. In that sense, studies with 
animal models of ASD analysed the gut phenotypic. The use of appropriate behavioural 
and experimental assays is required.  
According to the findings translated by preclinical studies to clinical studies and the role 
of gut microbiome alteration in ASD pathophysiology, more research is needed in this 
field to disclose the positive effects of different interventions and to disclose the 
possibility for novel treatment approaches, so there is an urgent need for large-scale, 
highly controlled, longitudinal human studies showing the causes and effects of dysbiotic 
gut states. One of the most considerable interventions could be probiotics, as a safer 
alternative to elimination diets, with their ability to target multiple physiological areas 
(Doenyas, 2018). In this sense, future studies must consider aspects such as the following: 
study design, intervention, adherence, safety assessment, strain specificity, bacterial 
quantification and microbial metabolites (Shane et al., 2010; Welch et al., 2011).  
Taking into consideration all of the aforementioned evidence, probiotics among other 
microbiota interventions could improve ASD symptoms, especially in executive 
symptoms, among others. These new perspectives would open a promising therapeutic 
perspective, however, nowadays clinical evidence is very limited, and it is necessary to 
perform more clinical trials in which authors explore the possible effects of such 
intervention on ASD patients.  
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Table 1. Altered gut microbiota in ASD. 
Altered gut microbiota Reference 
↑Clostridium (Parracho et al., 2005; Song 
et al., 2004) 
↑Sutterella spp.; ↑Ruminococcus torques; ↓Akkermansia 
muciniphila 
(Wang et al., 2011, 2013) 
↑Clostridium; ↑Sutterelaceae; ↑Enterobacteriacae;  
↓Bifidobacterium 
(De Angelis et al., 2013) 
↑Desulfovibrio; ↑Bacteroides vulgatus; ↑Ruminococcus; 
↓Bifidobacterium 
(Finegold et al., 2010) 
↑Collinsella; ↑Corynebacterium; ↑Dorea; ↑Lactobacillus; 
↓Alistipes; ↓Bilophila; ↓Dialister; ↓Parabacteroides; 
↓Veillonella 
(Strati et al., 2017) 
↓Bifidobacter; ↑Lactobacillus (Adams, 2011) 
↓Bacteroidetes; ↑Betaproteobactera (Williams et al., 2011) 
↑Sutterella (Williams et al., 2012) 
↓Prevotella; ↓Coprococcus; ↓Veillonellacea (Kang et al., 2013) 
↑Clostridia; ↑Ruminococcus; ↑Bacteroidetes; ↑Clostridium 
difficile 
(Finegold et al., 2002) 
↑Lactobacillaceae; ↑Bifidobacteraceae; ↑Veillonellaceae (Pulikkan et al., 2018) 
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Table 2. Preclinical and clinical studies about microbiota intervention and their effects on ASD behavioral symptoms. 
Preclinical studies     
Reference Intervention Population Variables Results 
(Hsiao, 2013) Probiotic 






Behavioral testing (pre-pulse 
inhibition, open field exploration, 
marble burying, social interaction 
and adult ultrasonic vocalizations) 
Microbial outcomes 
Metabolomics screening 
Bacteroides fragilis corrects gut permeability, alters 
microbial composition and ameliorates ASD-related 




Reference Intervention Population Variables Results 
(Sandler, 2000) Vancomycin (8 weeks) – 
Probiotic mixture 
(Lactobacillus acidophilus, 
L bulgaricus, and 






Psychologic Evaluations (assesment 
for behavior, communication, and 
social skills) 
Microbial outcomes 
During the probiotic administration, most parents 
reported substantial behavioral deterioration within 2 
weeks of discontinuance of vancomycin treatment. 
Because of difficulty in disguising the taste, probiotic 
treatment compliance was very poor in several children. 
Behavioral deterioration appeared to occur whether or 
34 
 
not the child was compliant with the probiotic therapy 
regimen.  
(Parracho, 2010) Probiotic (Lactobacillus 





Bowel function and GI symptoms 
Psychological analysis (DBC, TBPS) 
No significant effect as compared with placebo group 











21-day stool frequency diary prior 
and 21-day stool frequency diary 
following completion of treatment 
ATEC tool  
(speech/language/communication, 
sociability, sensory/cognitive  
awareness, and health/ physical/ 
behavior) 
Probiotic and immunomodulator Delpro® may have 
significant benefit in the treatment of GI distress and 
other ATEC signs and symptoms among this population 













GSRS: approximately 80% reduction of GI symptoms at 
the end of treatment. 
Improvements in symptoms of constipation, diarrhea, 
indigestion, and abdominal pain 
 
Behavioral ASD symptoms. 
improved significantly and remained improved 8 weeks 
after treatment ended. 
 
Results were maintained 8 weeks after the treatment. 
 
ABC: Aberrant Behavior Checklist; ADI-R: Autism Diagnostic Interview-Revised; ADOS 2: Autism Diagnostic Observation Schedule- Second 
Edition; ATEC: Autism Treatment Evaluation Checklist; CARS: Childhood Autism Rating Scale; CBCL 1.5-5 Child Behavior Checklist 1.5-5; 
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DBC: Development Behaviour Checklist ;DSR: Daily Stool record; GIRS: Gastrointestinal Symptom Rating Scale; GISI: Gastro-intestinal Severity 
Index; GMDS-ER: Griffiths Mental Development Scale-Extended Revised;  Mc Arthur-CDI: MacArthur-Bates Communicative Development 
Inventories; PGI-R: Parent Global Impressions; RBS-R: Repetitive Behavior Scale-Revised; SCQ: Social Communication Questionnaire; SRS: 
Social Responsiveness Scale; TBPS: Total Behaviour Problem score; VABS-II: Vineland Adaptive Behavior Scale II. 
 
 
